ArticleHistology and histopathology2025
Galangin alleviates gastric mucosal injury in rats with chronic atrophic gastritis by reducing ferroptosis.
Article in Histology and histopathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Aspirin Eugenol Ester Alleviates Gastric Injury by Inhibiting Ferroptosis and Oxidative Stress.Antioxidants (Basel, Switzerland) · 2026Article
- Targeting ferroptosis inInternational journal of oncology · 2026Review
- Spasmolytic Polypeptide-Expressing Metaplasia in Chronic Atrophic Gastritis and Its Role in the Progression From Gastritis to Gastric Cancer.Journal of digestive diseasesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveChronic atrophic gastritis (CAG) is a precancerous lesion and is the first stage in a multistep precancerous cascade that can lead to gastric adenocarcinoma. This study aimed to reveal the role and mechanism of galangin in CAG.
methodsRats were intragastrically administered a mixture of 2% sodium salicylate and 30% alcohol, forced to exercise, and fasted irregularly to establish CAG models. To explore the efficacy of galangin on CAG rats, we used Hericium erinaceus (HE) and omeprazole (Ome) as controls. The degree of gastric mucosal injury was assessed by H&E staining and immunohistochemistry. Perls staining and western blot analysis were used to assess iron content and enrichment of ferroptosis-related proteins. Reactive oxygen species and mitochondrial superoxide in the mucosa were visualized by probes. The morphology of cells was examined by transmission electron microscopy.
resultsOur data showed that galangin treatment alleviated gastric mucosal damage and reduced ferroptosis in CAG rats, manifested as decreased iron content, iron transporters and storage proteins, decreased ROS and mitochondrial superoxide, and partially restored cellular morphology. Of note, galangin at a high concentration had better treatment efficacy than HE but lower than Ome.
conclusionsThis study demonstrated that galangin reduced gastric mucosal injury in CAG rats by inhibiting ferroptosis. These findings provide a theoretical basis for its clinical application and broaden its potential applications.
Indexed as
Identifiers
39898405What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.